HER2-low Unresectable and/or Metastatic Breast Cancer in Russia
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
1,669actual
Sites
40
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-30 | actual | When the study began enrolling |
| Primary completion | 2025-03-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-14 | actual | The whole study's end, after follow-up |
| First posted | 2023-06-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer
Primary outcomes
what the primary-completion date above is the date OFTo study the overall prevalence of HER2-low among patients with HER2-negative mBC, based on reassessment of historical HER2 fixed tissue IHC stained slides assay in the Russian Federation
measured 12 months
To study the clinical-pathological, histopathological and demographic profiles of patients of HR-positive and HR-negative HER2-low status among unresectable and/or mBC patients identified as HER2-negative HR-positive/negative
measured 12 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed